A recent study shows that selenophosphate synthetase 2 (Sephs2), which is co-translationally incorporated into selenoproteins, is overexpressed in TNBC cells, providing new insight into the use of Sephs2 as a therapeutic target for treatment, because tumor aggressiveness can be associated with mRNA and protein concentrations (Nunziata et al., 2019). Here, SEPHS2 is linked to neoplasm.